Can You Use SGLT2 Inhibitors at eGFR Below 30?
Empagliflozin can be initiated down to eGFR 20 mL/min/1.73 m2 per its FDA label; dapagliflozin is labeled for initiation down to eGFR 25. Both can be continued as eGFR falls further, until dialysis or transplant. Glycemic effect fades below eGFR 30, but cardiorenal benefit persists across the spectrum. Expect an acute eGFR dip of 3–5 mL/min in the first 2–4 weeks that recovers on long-term follow-up.
Evidence review
Pivotal trials, effect sizes, and the populations they studied. PubMed identifiers link directly to the source.
DAPA-CKD (2020)
PMID 329703964,304 adults, eGFR 25–75, UACR 200–5000, ~67% diabetic
Dapagliflozin reduced composite renal outcome (≥50% eGFR decline, ESKD, renal/CV death) by 39% (HR 0.61, 95% CI 0.51–0.72). All-cause mortality reduced 31% (HR 0.69).
EMPA-KIDNEY (2023)
PMID 363311906,609 adults, eGFR 20–<45 or 45–<90 with UACR ≥200, mixed etiology
Empagliflozin reduced kidney disease progression or CV death 28% (HR 0.72, 95% CI 0.64–0.82). Benefit consistent across the eGFR 20–30 subgroup.
CREDENCE (2019)
PMID 309902604,401 with T2D and albuminuric CKD, eGFR 30–90
Canagliflozin reduced ESKD, doubling of creatinine, or renal/CV death 30% (HR 0.70, 95% CI 0.59–0.82). Stopped early for efficacy.
Practical decision algorithm
| If | Then |
|---|---|
| eGFR 20–30 with albuminuria (UACR ≥200) or T2D | Start empagliflozin 10 mg daily (labeled to eGFR 20); dapagliflozin 10 mg can be initiated if eGFR ≥25 per label. Continue through dialysis initiation. |
| Acute eGFR drop <30% in first 4 weeks | Expected physiologic dip — do not stop. Recheck at 4–12 weeks. |
| eGFR drop ≥30% from baseline | Hold, evaluate for volume depletion or concurrent ACEi/ARB/diuretic dose, then rechallenge. |
| On dialysis | Discontinue — no incremental benefit, increased UTI/GU risk. |
Guideline position
KDIGO 2024 CKD guideline: SGLT2 inhibitor is first-line (alongside RAS blockade) for CKD with albuminuria regardless of diabetes status, with initiation recommended down to eGFR 20 and continuation below 20 until dialysis. ADA 2026 Standards of Care: SGLT2 inhibitor with demonstrated CV/CKD benefit recommended in T2D with eGFR ≥20; continue below 20 in non-dialysis patients. FDA labels differ by agent: empagliflozin initiation to eGFR 20, dapagliflozin to eGFR 25.
Contraindications and cautions
- Type 1 diabetes (DKA risk)
- Recurrent genital mycotic infection or history of Fournier gangrene
- Active foot ulcer (relative)
- Hypotension (SBP <95) — stabilize first
- Initiating during acute illness with poor PO intake (DKA risk)